Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the radiation therapy oncology group

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 1, 2012, Pages 425-434

  MacHtay, Mitchell ^a   Bae, Kyounghwa ^b   Movsas, Benjamin ^c   Paulus, Rebecca ^b   Gore, Elizabeth M ^d   Komaki, Ritsuko ^e   Albain, Kathy ^f   Sause, William T ^g   Curran, Walter J ^h  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g LDS HOSPITAL   (United States)

^h EMORY UNIVERSITY   (United States)

Author keywords

Advanced non small cell lung carcinoma; Chemoradiotherapy; Local regional failure; Radiation oncology; Survival with respect to radiotherapy dose intensity

Indexed keywords

BIOLOGICALLY EFFECTIVE DOSE; CHEMORADIATION; CHEMORADIOTHERAPY; CHI-SQUARED; COVARIATES; DOSE INTENSITY; HAZARD RATIO; LUNG CARCINOMA; MULTI VARIATE ANALYSIS; NON-SMALL CELL LUNG CARCINOMATA; OVERALL SURVIVAL; PROPORTIONAL HAZARD MODELS; RADIATION ONCOLOGY; RADIATION THERAPY ONCOLOGY GROUPS; SURVIVAL WITH RESPECT TO RADIOTHERAPY DOSE INTENSITY;

BIOLOGICAL ORGANS; CELLS; HAZARDS; LAKES; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT MONITORING; PESTICIDE EFFECTS;

RADIOTHERAPY;

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; VINBLASTINE;

EID: 83955163001     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.09.004     Document Type: Article

References (39)

1. C.A. Perez, T.F. Pajak, and P. Rubin Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the RTOG Cancer 59 1987 1874
2. P. Marino, A. Preatoni, and A. Cantoni Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis Cancer 76 1995 593 601
3. R.O. Dillman, J. Herndon, and S.L. Seagren Improved survival in stage III non-small cell lung cancer: Seven-year followup of cancer and leukemia group B (CALGB) 8433 trial J Natl Cancer Inst 88 1996 1210 1215
4. K. Furuse, M. Fukuoka, and M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer J Clin Oncol 17 1999 2692 2699
5. M. Machtay, C. Hsu, and R. Komaki Effect of overall treatment time on outcome after concurrent chemoradiation for locaclly advnced non-small cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience Int J Radiat Oncol Biol Phys 63 2005 667 671
6. W. Sause, P. Kolesar, and S.I. Taylor Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group and Southwest Oncology Group Chest 117 2000 358 364
7. R. Byhardt, C.B. Scott, and D. Ettinger Concurrent hyperfractionated irradiation and chemotheray for unresectable NSCLC: Results of RTOG 90-15 Cancer 75 1995 2237 2244
8. J.S. Lee, C. Scott, and R. Komaki Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: RTOG Protocol 91-06 J Clin Oncol 14 1996 1055 1064
9. R. Komaki, W. Seiferheld, and D. Ettinger Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable NSCLC: Long term followup of RTOG 92-04 Int J Radiat Oncol Biol Phys 53 2002 548 557
10. K.S. Albain, R.S. Swann, and V.W. Rusch Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: A phase III randomised controlled trial Lancet 374 2009 379 386
11. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with urnsected stage III NSCLC: RTOG 9410 (abstr. #2499). In: Proc Am Soc Clin Oncol (ASCO); 2003; Chicago; 2003. p. 621.
12. B. Movsas, C. Scott, and C. Langer Randomized trial of amifostine in locally advanced non-small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: RTOG 98-01 J Clin Oncol 23 2005 2145 2154
13. J. Fowler Brief summary of radiobiological principles in fractionated radiotherapy Semin Radiat Oncol 2 1992 16 21
14. J.F. Fowler, and R. Chappell Non-small cell lung tumors repopulate rapidly during radiation therapy Int J Radiat Oncol Biol Phys 46 2000 516 517
15. C.T. Smith, P.R. Williamson, and A.G. Marson Investigating heterogeneity in an individual patient data meta-analysis of time to even outcomes Stat Med 24 2005 1307 1311
16. D. Collett Modelling survival data in medical research 1994 Chapman & Hall New York
17. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
18. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Annual Statistics 16 1988 1141 1143
19. D.R. Cox Regression models and life tables J Royal Stat Soc 34 1972 187 202
20. J. Fine, and R.J. Gray A proportional hazards model for the subdistribution of a competing risk J Am Stat Assoc 94 1999 496 509
21. Curran WJ, Scott C, Langer C, et al. Phase III comparison of sequential vs. concurrent chemoradiation for pts with unrsected stage III NSCLC: Initial report of RTOG 9410 (abstr. #1891). In: Proc Am Soc Clin Oncol (ASCO); 2000; New Orleans; 2000. p. 484a.
22. S. Yuan, X. Sun, and M. Li A randomized study of involved field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer Am J Clin Oncol 30 2007 239 244
23. Bradley JD, Graham M, Swann RS, et al. Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with inoperable NSCLC. In: Proc Am Soc Clin Oncol (ASCO); 2005; Orlando: J Clin Oncol (PASCO suppl); 2005. p. 7063.
24. Bradley J, Bae K, Graham M, et al. Initial primary analysis of phase II for RTOG 0117: A phase I/II dose intensification study using 3D conformal radiaiton therapy and concurrent chemotherapy for patients with inoperable, non-small cell lung cancer (NSCLC) (abstr. B.5.2). In: World Lung Congress of the International Association for the Study of Lung Cancer (IASLC); 2009; San Fracisco: J Thor Oncol suppl.; 2009.
25. M.A. Socinski, A.W. Blackstock, and J.A. Bogart Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in sage III non-small cell lung cancer: CALGB 30105 J Clin Oncol 26 2008 2457 2463
26. T.E. Stinchcombe, D.E. Morris, and C.B. Lee Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer J Thorac Oncol 3 2008 250 257
27. RTOG 0617. American College of Radiology, 2009. (Accessed 12/1/2009, 2009, at http://www.rtog.org/members/protocols/0617/0617.pdf
28. Timmerman RD, Paulus R, Galvin J, et al. RTOG 0236: Stereotactic body radiation therapy (SBRT) to treat medically inoperable early stage lung cancer patients (abstr. #5). In: Proc Am Soc Radiat Oncol (ASTRO); 2009; Chicago: Int J Radiat Oncol Biol Phys 2009. p. 3.
29. H. Onishi, H. Shirato, and Y. Nagata Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study J Thorac Oncol 2 7 Suppl. 3 2007 S94 S100
30. Bradley JD, Graham MV, Moughan J, et al. Phase I/II results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT ahnd concurrent chemotherapy for patients with inoperable NSCLC: PD5-2-4. In: IASLC; 2007; Seould: J Thor Oncol 2007. p. S476.
31. E.E. Vokes, J.E. Herndon 2nd, and M.J. Kelley Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B J Clin Oncol 25 2007 1698 16704
32. H. Choy, R.F. DeVore, and K.R. Hande A Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperarble non-small cell lung cancer (A Vanderbilt cancer center affiliate network study) Int J Radiat Oncol Biol Phys 47 2000 931 937
33. D.R. Gandara, K. Chansky, and K.S. Albain Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: A phase II Southwest Oncology Group Study (S9504) Clin Lung Cancer 8 2006 116 121
34. K. Kelly, K. Chansky, and L.E. Gaspar Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
35. N. Hanna, M. Neubauer, and C. Yiannoutsos Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: The Hoosier Oncology Group and U.S. Oncology J Clin Oncol 26 2008 5755 5760
36. M.P. MacManus, R.J. Hicks, and D.L. Ball F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment Cancer 92 2001 886 895
37. C.P. Belani, H. Choy, and P. Bonomi Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: A randomized phase II locally advanced multi-modality protocol J Clin Oncol 23 2005 5883 5891
38. B. Jeremic, Y. Shibamoto, and L. Acimovic Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study J Clin Oncol 14 1996 1065 1070
39. Schild S, Graham D, Hillman S, et al. Survival of patients treated with high dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC) (abstr. #7544). In: Am Soc Clin Oncol (ASCO); 2009; Orlando: J. Clin. Oncol. ASCO proceedings; 2009. p. 7544.